Evidence map›Paper›PMID 32021173›Full record

Trial reportInternational journal of nanomedicine2020

New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine - Pre-Clinical and Pilot Human Clinical Investigations.

Menka Khoobchandani, Kavita K Katti, Alice Raphael Karikachery, Velaphi C Thipe, Deepak Srisrimal, Darsha Kumar Dhurvas Mohandoss, Rashmi Dhurvas Darshakumar, Chintamani M Joshi, Kattesh V Katti

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 152 citations in OpenAlex.

  1. Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Progress and prospects of metal-based immunotherapy in breast cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  8. Investigating theRSC advances · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. From Nature to Nanotechnology: The Bioactivities of Mangiferin Explored.Nanotechnology, science and applications · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Menka KhoobchandaniDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA.
Kavita K KattiDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA.
Alice Raphael KarikacheryDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA.
Velaphi C ThipeDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA.ORCID 0000-0003-4426-6567
Deepak SrisrimalDhanvantari Nano Ayushadi Pvt Ltd, Chennai 600017, India.
Darsha Kumar Dhurvas MohandossDhanvantari Nano Ayushadi Pvt Ltd, Chennai 600017, India.
Rashmi Dhurvas DarshakumarDhanvantari Nano Ayushadi Pvt Ltd, Chennai 600017, India.
Chintamani M JoshiDhanvantari Nano Ayushadi Pvt Ltd, Chennai 600017, India.
Kattesh V KattiDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA.
University of Missouri · USDhanvantari Ayurveda College Hospital and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe overarching objective of this investigation was to investigate the intervention of green nanotechnology to transform the ancient holistic Ayurvedic medicine scientifically credible through reproducible formulations and rigorous pre-clinical/clinical evaluations.

methodsWe provide, herein, full details: (i) on the discovery and full characterization of gold nanoparticles-based Nano Swarna Bhasma (henceforth referred to as NSB drug); (ii) In vitro anti-tumor properties of NSB drug in breast tumor cells; (iii) pre-clinical therapeutic efficacy studies of NSB drug in breast tumor bearing SCID mice through oral delivery protocols and (iv) first results of clinical translation, from mice to human breast cancer patients, through pilot human clinical trials, conducted according to the Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (abbreviated as AYUSH) regulatory guidelines of the Government of India in metastatic breast cancer patients.

resultsThe preclinical in vitro and in vivo investigations, in breast tumor bearing mice, established unequivocally that the NSB Nano-Ayurvedic medicine-gold nanoparticles-based drug is highly effective in controlling the growth of breast tumors in a dose dependent fashion in vivo. These encouraging pre-clinical results prompted us to seek permission from the Indian Government's holistic medicine approval authority, AYUSH, for conducting clinical trials in human patients. Patients treated with the NSB drug capsules along with the "standard of care treatment" (Arm B) exhibited 100% clinical benefits when compared to patients in the treatment Arm A, thus indicating the tremendous clinical benefits of NSB drug in adjuvant therapy.

conclusionWe have succeeded in clinically translating, from mice to humans, in using proprietary combinations of gold nanoparticles and phytochemicals to develop the Nano-Ayurvedic drug: Nano Swarna Bhasma (NSB), through innovative green nanotechnology, for treating human metastatic breast cancer patients.

Indexed as

Administration, OralAdultAnimalsBreast NeoplasmsCell Line, TumorFemaleGoldGreen Chemistry TechnologyHumansIndiaMangiferaMedicine, AyurvedicMetal NanoparticlesMice, SCIDMiddle AgedNanotechnologyGoldmangiferinXanthonesgold nanoparticlesmangiferinmango peelNano Swarna BhasmaNSBpilot clinicaltriple negative breast tumor

Identifiers

PMID32021173
PMCPMC6970107
OpenAlexW3000302655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.